Thousand Oaks biotech heavyweight Amgen reported increases in fourth quarter and full-year revenue Jan. 29, alongside strong increases in net income boosted by share repurchase programs and tax windfalls. But the company delivered a weaker-than-expected forecast for fiscal 2019, prompting shares to slip by around 2.4 percent in after-hours trading to $187.50, down from a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
